Medical Communications

Showing 15 posts of 6408 posts found.

PharmNovo submits CTA for non-addictive neuropathic pain therapeutic

July 1, 2025 Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome

Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025 Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …

Inizio Evoke appoints Kelly Cusumano to drive strategic growth and innovation

June 27, 2025 Business Services, Marketing Consultancies, Medical Communications Corporate, Evoke Comms, Inizio Evoke, business strategist, executive vice president, marketing and communications

Inizio Evoke, a global health marketing and communications platform, has appointed Kelly Cusumano as executive vice president, growth and client …

PMGroup/Visions4Health unveil Excellence in Healthcare Partnerships Awards

June 26, 2025 Medical Communications CHASE, Corporate, Excellence in Healthcare Partnerships Awards, NHS ConfedExpo, PMGroup, Visions4Health

PMGroup Worldwide and Visions4Health have launched the Excellence in Healthcare Partnerships (EHP) Awards to recognise collaborations that deliver measurable benefits …
money_pills_2

Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses

June 26, 2025 Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation

Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …

NHS ConfedExpo 2025: a platform for change in UK health and care

June 24, 2025 Medical Communications Accenture, AstraZeneca, Corporate, Excellence in healthcare Partnership (EHP) Awards, Manchester, NHS ConfedExpo, NHS Confederation, NHS England, Novartis UK, Visions4Health

This year’s NHS ConfedExpo took place on 11 to 12 June at Manchester Central, bringing together around 9,000 attendees. Among …
blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

June 23, 2025 Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …

NICE recommends spevigo for rare and severe psoriasis flares

June 20, 2025 Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …

Alan Perkins awarded MBE for services to patient care and clinical science

June 19, 2025 Medical Communications Devices, MBE, Serac Life Sciences, medical imaging technology, molecular imaging, nuclear medicine, scientific advisor

Serac Life Sciences has announced that Alan Perkins, scientific advisor to its subsidiaries Serac Healthcare and Serac Imaging Systems, has …
AstraZeneca_drug_discovery

Bristol Myers Squibb to present positive new data on lymphoma treatment

June 18, 2025 Medical Communications, Research and Development Bristol Myers Squibbs, CAR T-cell therapy, International Conference on Malignant Lymphoma, Oncology, relapsed or refractory marginal zone lymphoma

Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) …
The Gateway to Local Adoption Series

Latest content